<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218387</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-16368-1</org_study_id>
    <secondary_id>R01DA016368</secondary_id>
    <secondary_id>R01-16368-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218387</nct_id>
  </id_info>
  <brief_title>Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1</brief_title>
  <official_title>CBT and Modafinil for Cocaine Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine addiction is a serious health problem with no available medical treatment for
      preventing relapse. Modafinil, a medication that enhances mood, increases energy, and
      improves concentration, may be useful in preventing relapse among individuals with cocaine
      addiction. This study will evaluate the effectiveness of modafinil, in combination with
      cognitive behavior therapy (CBT), to prevent drug relapse among cocaine addicts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of a medication to treat cocaine addiction specifically by lessening
      withdrawal symptoms has been a primary focus of research. Common cocaine withdrawal symptoms
      include depression, lack of energy, and poor concentration. Modafinil, a central nervous
      system stimulant, is a medication that can speed up physical and mental processes in the
      brain. It is currently used to treat narcolepsy, a condition that causes excessive
      sleepiness. Modafinil enhances mood, increases energy, and improves concentration in people
      with narcolepsy. Modafinil may also cause the same effects in individuals addicted to
      cocaine, thereby countering the symptoms of cocaine withdrawal. The purpose of this study is
      to compare the effectiveness of modafinil plus CBT versus placebo plus CBT for treating
      cocaine dependence.

      A 2-week screening period will be followed by an 8-week treatment phase. Participants will be
      randomly assigned to receive either 200 mg of modafinil, 400 mg of modafinil, or placebo on a
      daily basis for the 8 weeks of treatment. During this time, participants will be asked to
      report the number of days that they use and do not use cocaine. This will be confirmed three
      times a week with urine tests. Mood, level of daytime sleepiness, and symptoms of cocaine
      withdrawal and cocaine &quot;high&quot; will be evaluated. Compliance with study medication will be
      assessed with urine and blood tests. Medication side effects will be monitored through
      physical examinations, routine lab tests, ECGs, and self-reports. Follow-up evaluations will
      occur 4 and 8 weeks following the end of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cocaine Non-use Days</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of cocaine non-use days was determined by Urine Drug Screen tests which confirmed presence (or no presence) of benzoylecgonine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With New Use</measure>
    <time_frame>8 weeks</time_frame>
    <description>New Use is defined as a period of at least 7 days abstinence followed by a positive urine drug screen.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>200mg Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg Modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg Modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>200mg Modafinil</description>
    <arm_group_label>200mg Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>400mg Modafinil</description>
    <arm_group_label>400mg Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seeking treatment for cocaine dependence

          -  Meets DSM-IV diagnosis criteria for cocaine dependence as determined by Mini-SCID
             interview

          -  If female, willing to use effective contraception throughout the study

          -  Lives within 50 miles of the research center and has reliable transportation

        Exclusion criteria:

          -  Meets DSM-IV/Mini-SCID diagnosis criteria for dependence on any drugs other than
             cocaine, alcohol, nicotine, or marijuana

          -  Physiologic dependence on alcohol requiring medical detoxification, on either an
             inpatient or outpatient basis

          -  Current psychiatric disorder, including depression, schizophrenia, bipolar affective
             disorder, organic brain disease, dementia, or other types of psychosis

          -  Recent suicidal or homicidal attempts within 60 days of study entry

          -  Suicidal or homicidal ideation within 30 days of study entry

          -  Meets diagnosis criteria from the Differential Diagnosis of Psychotic Disorders
             section of Mini-SCID for a history of psychotic symptoms during a period of cocaine
             use (e.g., persistent hallucinations and delusions)

          -  Serious medical illness, including left ventricular hypertrophy, mitral valve
             prolapse, left bundle branch block, heart attack, angina, serious liver disease
             (transaminase levels four times greater than normal), and kidney, neurologic,
             metabolic, neoplastic, nutritional, inflammatory, or endocrine disorders

          -  Required by the court to obtain treatment for cocaine dependence

          -  Not seeking treatment for cocaine dependence

          -  Participated in cocaine treatment (clinical or research) within 30 days of study entry

          -  Anticipating elective surgery or hospitalization within 20 weeks of study entry

          -  Known or suspected hypersensitivity to modafinil

          -  Use of any of the following medications within 14 days of study entry: selective
             serotonin reuptake inhibitor antidepressants, tricyclic antidepressants, dopamine
             agonists, and other psychotropic medications, including anticonvulsants,
             antipsychotics, anxiolytics, or psychostimulants

          -  Currently taking medications that could adversely interact with study medications,
             including azole-type antifungals, cyclosporine, warfarin, theophylline, or
             carbamazepine

          -  Currently taking any medications that induce or inhibit CYP3A4 metabolic pathways

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Malcolm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>December 19, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Robert Malcolm</investigator_full_name>
    <investigator_title>Professor of Psychiatry, Family Medicine &amp; Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cocaine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>200mg Modafinil</title>
          <description>200mg Modafinil
Modafinil: 200mg Modafinil</description>
        </group>
        <group group_id="P2">
          <title>400mg Modafinil</title>
          <description>400mg Modafinil
Modafinil: 400mg Modafinil</description>
        </group>
        <group group_id="P3">
          <title>Matching Placebo</title>
          <description>Matching Placebo
Matching Placebo: Matching Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>200mg Modafinil</title>
          <description>200mg Modafinil
Modafinil: 200mg Modafinil</description>
        </group>
        <group group_id="B2">
          <title>400mg Modafinil</title>
          <description>400mg Modafinil
Modafinil: 400mg Modafinil</description>
        </group>
        <group group_id="B3">
          <title>Matching Placebo</title>
          <description>Matching Placebo
Matching Placebo: Matching Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="7.1"/>
                    <measurement group_id="B2" value="40.4" spread="7.2"/>
                    <measurement group_id="B3" value="40.0" spread="8.8"/>
                    <measurement group_id="B4" value="39.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Cocaine Non-use Days</title>
        <description>Number of cocaine non-use days was determined by Urine Drug Screen tests which confirmed presence (or no presence) of benzoylecgonine levels.</description>
        <time_frame>8 weeks</time_frame>
        <population>The amount of subjects represent those that completed 8 weeks of treatment. The exclusion of alcohol dependence listed in the exclusion criteria within the protocol is referring to a physiological dependence on alcohol requiring a medical detox.</population>
        <group_list>
          <group group_id="O1">
            <title>200mg Modafinil</title>
            <description>200mg Modafinil
Modafinil: 200mg Modafinil</description>
          </group>
          <group group_id="O2">
            <title>400mg Modafinil</title>
            <description>400mg Modafinil
Modafinil: 400mg Modafinil</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching Placebo
Matching Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cocaine Non-use Days</title>
          <description>Number of cocaine non-use days was determined by Urine Drug Screen tests which confirmed presence (or no presence) of benzoylecgonine levels.</description>
          <population>The amount of subjects represent those that completed 8 weeks of treatment. The exclusion of alcohol dependence listed in the exclusion criteria within the protocol is referring to a physiological dependence on alcohol requiring a medical detox.</population>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Alcohol Dependence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="2.4"/>
                    <measurement group_id="O2" value="17.1" spread="2.3"/>
                    <measurement group_id="O3" value="9.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol Dependence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="2.5"/>
                    <measurement group_id="O2" value="9.4" spread="2.5"/>
                    <measurement group_id="O3" value="12.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With New Use</title>
        <description>New Use is defined as a period of at least 7 days abstinence followed by a positive urine drug screen.</description>
        <time_frame>8 weeks</time_frame>
        <population>The amount of subjects represent those that completed 8 weeks of treatment. The exclusion of alcohol dependence listed in the exclusion criteria within the protocol is referring to a physiological dependence on alcohol requiring a medical detox.</population>
        <group_list>
          <group group_id="O1">
            <title>200mg Modafinil</title>
            <description>200mg Modafinil
Modafinil: 200mg Modafinil</description>
          </group>
          <group group_id="O2">
            <title>400mg Modafinil</title>
            <description>400mg Modafinil
Modafinil: 400mg Modafinil</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching Placebo
Matching Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With New Use</title>
          <description>New Use is defined as a period of at least 7 days abstinence followed by a positive urine drug screen.</description>
          <population>The amount of subjects represent those that completed 8 weeks of treatment. The exclusion of alcohol dependence listed in the exclusion criteria within the protocol is referring to a physiological dependence on alcohol requiring a medical detox.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Alcohol Dependence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol Dependence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>200mg Modafinil</title>
          <description>200mg Modafinil
Modafinil: 200mg Modafinil</description>
        </group>
        <group group_id="E2">
          <title>400mg Modafinil</title>
          <description>400mg Modafinil
Modafinil: 400mg Modafinil</description>
        </group>
        <group group_id="E3">
          <title>Matching Placebo</title>
          <description>Matching Placebo
Matching Placebo: Matching Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Racing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rapid Heart Rate</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Ache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="43"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Jitteriness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Malcolm, MD</name_or_title>
      <organization>Medical University of SC</organization>
      <phone>843-792-1901</phone>
      <email>malcomr@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

